Last reviewed: June 19, 2026
Last updated: June 19, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide and tirzepatide are the two most popular prescription medications for weight loss, but they work through different mechanisms. While semaglutide activates the GLP-1 receptor alone, tirzepatide targets both GLP-1 and GIP receptors, potentially offering greater appetite suppression and metabolic benefits. Clinical trials show tirzepatide users lost an average of 22.5% of body weight over 72 weeks, compared to 14.9% with semaglutide at comparable doses.
How Semaglutide and Tirzepatide Work Differently
Semaglutide mimics the glucagon-like peptide-1 (GLP-1) hormone, which slows stomach emptying, increases feelings of fullness, and helps regulate blood sugar levels. This single-pathway approach has been proven effective for weight reduction and has become widely recognized since its introduction to the market. Millions of patients have used semaglutide-based therapies with measurable results in appetite control and weight management.
Tirzepatide activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, creating a dual-action effect. By engaging two separate hunger and metabolic pathways simultaneously, tirzepatide may amplify satiety signals to the brain more powerfully than semaglutide alone. This dual-receptor mechanism represents a newer approach to weight management that addresses appetite suppression from multiple angles at once.
Clinical Trial Results: Weight Loss Outcomes
The STEP clinical trial program evaluated semaglutide's effectiveness across multiple studies, demonstrating an average weight loss of 14.9% of body weight when combined with lifestyle changes over 68 weeks. Participants taking the highest doses showed weight reductions ranging from 10% to 16% depending on dosing protocol and individual factors. These results established semaglutide as an effective option for chronic weight management in adults with obesity or overweight conditions.
Tirzepatide's SUMO clinical trial program showed participants lost an average of 22.5% of their body weight over 72 weeks at the highest doses studied. In head-to-head comparisons within the trials, tirzepatide consistently outperformed semaglutide across all dosing levels tested. The magnitude of this difference suggests that dual-pathway activation may offer additional metabolic advantages for weight loss compared to single-pathway approaches.
Side Effects and Tolerability Differences
Both medications commonly cause gastrointestinal side effects including nausea, vomiting, diarrhea, and constipation, particularly during dose escalation phases. These effects typically decrease over time as the body adapts to the medication, with most patients experiencing mild to moderate symptoms that improve within weeks. Serious adverse events are rare with both compounds when used as directed under medical supervision.
Tirzepatide users report similar frequency of side effects to semaglutide users in clinical trials, though the intensity may vary between individuals. Some patients experience slightly better tolerability with one medication over the other due to genetic factors affecting peptide receptor sensitivity. PlexusDx's Precision Peptide Genetic Test identifies your genetic predispositions to GLP1R and GIPR pathway variations, helping predict which medication may work better with fewer side effects for your unique biology.
Cost, Access, and PlexusDx Compounding Options
PlexusDx offers both semaglutide and tirzepatide through licensed 503A compounding pharmacies, serving all 50 states without requiring insurance or membership fees. Compounded semaglutide injections start at $149 per month, while tirzepatide injections begin at $249 per month, with your dose potentially increasing without price changes across commitment tiers. Both medications are HSA and FSA eligible, making them accessible to patients seeking affordable, personalized weight loss therapy.
Beyond standard options, PlexusDx provides GLP-Squared, a dual-compound injection combining semaglutide and tirzepatide for patients seeking maximum dual-pathway activation starting at $249 per month. The Precision Peptide Genetic Test ($99 after your first month) analyzes 49 peptides across 14 pathways to identify which medication aligns best with your genetic makeup, helping optimize outcomes before committing to a specific therapy. This personalized approach removes guesswork from selecting between these two powerful weight loss options.
Which Medication Might Be Right for You
Semaglutide may be an excellent choice if you seek a well-established, extensively studied medication with a long safety track record and prefer a simpler single-pathway approach. Patients new to GLP-1 therapy often tolerate semaglutide well, and its lower starting cost makes it accessible for budget-conscious individuals beginning their weight loss journey. If you have specific contraindications to dual-pathway activation or prefer a more gradual introduction to appetite-suppressing medications, semaglutide offers a proven alternative.
Tirzepatide may deliver superior results if you have struggled with weight loss using other methods and desire the most clinically robust weight reduction available today. The dual GLP-1 and GIP pathway activation produces stronger appetite suppression and metabolic improvement for many patients, particularly those with genetic variations favoring these receptors. Consulting with a PlexusDx provider and completing the Precision Peptide Genetic Test ensures you select the medication most likely to succeed based on your individual biology rather than guesswork.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can I switch from semaglutide to tirzepatide if I'm not seeing results?
Yes, many patients safely transition from semaglutide to tirzepatide under medical supervision when weight loss plateaus or expectations aren't met. A PlexusDx provider can evaluate your progress and genetic factors to determine if tirzepatide's dual-pathway mechanism may unlock better results. The transition typically involves a brief washout period and careful dose titration to minimize side effects during the switch.
Which medication causes more nausea?
Clinical trials show similar nausea rates between semaglutide and tirzepatide, with both medications causing mild to moderate nausea in early weeks that typically resolves as your body adjusts. Individual tolerability varies based on genetics, metabolism, and dose escalation pace rather than the medication itself. Your genetic profile revealed by the Precision Peptide Genetic Test may predict which option your body will tolerate best.
Is PlexusDx tirzepatide FDA-approved?
PlexusDx tirzepatide is compounded by licensed 503A pharmacies using FDA-approved active pharmaceutical ingredients, but the compounded final product is not itself FDA-approved. Compounding allows for personalized dosing and formulations not available through retail pharmacies. All PlexusDx medications maintain rigorous quality standards and are prepared under strict pharmaceutical guidelines.
What's the difference between oral and injection forms?
Injections typically achieve higher blood levels and faster onset of action, while oral forms provide convenience and avoid needles but may have variable absorption. PlexusDx offers both semaglutide and tirzepatide as injections starting at $149 and $249 monthly respectively, with oral options available at higher price points. Your provider helps determine which delivery method suits your lifestyle and goals.
How does the Precision Peptide Genetic Test help choose between these medications?
PlexusDx's genetic test analyzes your GLP1R rs6923761 and GIPR rs1800437 variants among 150+ insights, revealing which peptide pathways your body responds to most effectively. Patients with certain GLP1R variants may achieve better outcomes with semaglutide, while those with favorable GIPR activation may benefit more from tirzepatide's dual approach. This personalized data transforms the semaglutide versus tirzepatide decision from guesswork into precision medicine based on your unique biology.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Can Wegovy Cause Constipation? What You Need to Know About This Common Side Effect
Why Do People Gain Weight Back After Stopping Ozempic?